No Data
Atlassian And Amazon Web Services Announce A Multi-Year Strategic Collaboration Agreement To Expedite Cloud Transformation And Deliver Advanced AI And Security Capabilities To Enterprise Customers
YieldMax META Option Income Strategy ETF Declares $0.375 Dividend
Eli Lilly and Co announced the comparative trial results: Zepbound's weight-loss effect is better than Novo Nordisk's Wegovy.
eli lilly and co announced on Wednesday that in a comparative trial, its weight loss drug Zepbound had a greater weight loss effect than the competitor novo-nordisk a/s's similar drug Wegovy; eli lilly is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.
Marvell Technology Surges as Wall Street Praises Its 'All in' AI Mantra
Better than Wegovy! eli lilly and co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, with a 2.5% pre-market surge.
Participants using Wegovy from novo-nordisk a/s only experienced a 14% reduction. This result presents eli lilly and co with an opportunity to surpass, especially with the obesity drug market expected to reach 130 billion USD by the end of this decade.
TEMU aims to dethrone amazon.
Invade the opponent's hinterland.